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Abstract
Glycogen storage disease type 1a (GSD Ia) is an inborn error of metabolism caused by mutations in the G6PC gene, encoding
the catalytic subunit of glucose-6-phosphatase. Early symptoms include severe fasting intolerance, failure to thrive and
hepatomegaly, biochemically associated with nonketotic hypoglycemia, fasting hyperlactidemia, hyperuricemia and
hyperlipidemia. Dietary management is the cornerstone of treatment aiming at maintaining euglycemia, prevention of
secondary metabolic perturbations and long-term complications, including liver (hepatocellular adenomas and
carcinomas), kidney and bone disease (hypovitaminosis D and osteoporosis). As impaired vitamin A homeostasis also
associates with similar symptoms and is coordinated by the liver, we here analysed whether vitamin A metabolism is
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4 (RBP4) were significantly increased in both GSD Ia patients and L-G6pc−/− mice. In contrast, hepatic retinol levels were
significantly reduced in L-G6pc−/− mice, while hepatic retinyl palmitate (vitamin A storage form) and RBP4 levels were not
altered. Transcript and protein analyses indicate an enhanced production of retinol and reduced conversion the retinoic
acids (unchanged LRAT, Pnpla2/ATGL and Pnpla3 up, Cyp26a1 down) in L-G6pc−/− mice. Aberrant expression of genes
involved in vitamin A metabolism was associated with reduced basal messenger RNA levels of markers of inflammation
(Cd68, Tnfα, Nos2, Il-6) and fibrosis (Col1a1, Acta2, Tgfβ, Timp1) in livers of L-G6pc−/− mice. In conclusion, GSD Ia is associated
with elevated serum retinol and RBP4 levels, which may contribute to disease symptoms, including osteoporosis and
hepatic steatosis.
Introduction
Glycogen storage disease type 1a (GSD Ia or von Gierke disease)
is an autosomal recessive inherited disorder of carbohydrate
metabolism. Mutations in G6PC, encoding the catalytic subunit
of glucose-6-phosphatase (G6PC), limit the production of glu-
cose from glucose-6-phosphate (G6P) leading to hepatic glyco-
gen accumulation and life-threatening hypoglycemia in times
of inadequate dietary carbohydrate intake. In addition, GSD
Ia is associated with hepatic steatosis, hyperlipidemia, hyper-
lactacidaemia, hepatocellular tumor formation and intestinal
and renal impairments (1). Untreated GSD Ia patients display a
protruding abdomen, hepatomegaly, wasted muscles, a bleeding
tendency, truncal obesity, a rounded doll face and short stature.
No cure is available yet and prevention of hypoglycemia and
related metabolic dysfunctions are the main goals of dietary
management and control of GSD Ia (2). In addition, GSD Ia has
been associated with vitamin D deficiency. Suboptimal levels
of serum 25-hydroxyvitamin-D (<30 ng/ml) were observed in
most patients in a single center study of 20 patients, even
if they were supplemented with vitamin D and calcium (3).
Restrictive dietary plans, intestinal malabsorption, poor compli-
ance to dietary plans and metabolic derangements may cause
hypovitaminosis D in GSD Ia patients (3). Hypomagnesaemia,
hypercalciuria and low tubular resorption of phosphate, along
with vitamin D deficiency may reduce bone mineral content
and matrix formation in GSD Ia and increase the risk of bone
fractures and osteoporosis (4). Besides vitamin D, very limited
information is available about other potential vitamins deficien-
cies in GSD Ia. Vitamin A may be particularly relevant for GSD Ia
as these patients develop significant hepatic pathologies, such
as hepatic steatosis, hyperlipidemia and adenomas that may
affect the liver’s role in regulating vitamin A homeostasis.
Vitamin A is an essential fat-soluble vitamin and ∼80% of
the total vitamin A pool is stored as retinyl esters, mainly retinyl
palmitate, in the liver. White adipose tissue (WAT) contains the
second-largest pool of vitamin A (10–20%). Adequate hepatic
storage is required to maintain plasma retinol levels around
2 μmol/L in healthy humans (1–1.5 μmol/L in mice) (5). Vitamin
A plays important physiological roles in vision, reproduction,
growth, development, immunity and metabolic programs (6).
Impaired triglyceride and/or cholesterol metabolism often asso-
ciates with impaired vitamin A metabolism and homeostasis
(7, 8). Indeed, reduced serum retinol levels are associated with
hepatic steatosis (9, 10), hypertriglyceridemia, glucose intoler-
ance, insulin resistance and obesity (11, 12). On the other hand,
excess of vitamin A metabolites may also cause hyperlipidemia
by modulating hepatic triglyceride synthesis and very low-
density lipoprotein (VLDL) production (13, 14). As steatosis
and hypertriglyceridemia are prevalent metabolic symptoms
in GSD Ia patients (1), it is relevant to determine whether this
also associates with abnormal circulating vitamin A levels, as
this may affect immune regulation, tissue differentiation and
metabolic pathways in these patients. Thus, the aim of this study
was to determine whether vitamin A metabolism is affected in
GSD Ia patients and in liver-specific G6pc−/− knock-out mice.
Results
GSD Ia patients and L-G6pc−/− mice have elevated
serum retinol levels
Twenty-two GSD Ia patients, all from different families, were
included in this study and their general characteristics are pre-
sented in Table I. Mean serum triglyceride and cholesterol levels
were above normal levels and all patients show hepatic steatosis,
with mildly elevated serum AST and γ GT levels. Seven (7) out
of 22 patients showed osteopenia/osteoporosis. Proteinuria was
observed in only 3 patients. Similarly, only 3 out of 22 patients
showed insufficient serum 25(OH)D levels (<30 nmol/L). Serum
retinol levels were determined in the 22 GSD Ia patients (mean
age 26.1 ± 10.1) and 20 age- and sex-matched healthy controls
(mean age 25.7 ± 10.2) (Fig. 1A). Circulating retinol levels were
significantly increased in GSD Ia patients as compared to the
healthy controls (2.96 ± 0.22 versus 2.31 ± 0.12 μM, respectively),
with 10 out of 22 patients showing serum retinol levels above
2.7 μmol/L. No correlation was observed between serum retinol
levels and sex or age of the patients and controls (Fig. 1B). We
next aimed to analyze whether the elevated serum retinol levels
are also observed in a mouse model of GSD Ia (L-G6pc−/− mice)
(15), and if so, what molecular mechanisms may be involved.
The induction of the GSD Ia phenotype in L-G6pc−/− mice was
supported by: 1) almost complete absence of G6pc mRNA 10 days
after tamoxifen treatment (Supplementary Fig. S3A), 2) increased
liver weight (+47%); 3) elevated hepatic triglyceride levels (both
concentration (+56%) and total pool (+120%), 4) minor effects on
free cholesterol levels, but an increase in total hepatic pool of
total cholesterol and 5) fasting hypoglycemia, when compared
to control mice (Supplementary Fig. S1A). Excessive lipid accu-
mulation in the L-G6pc−/− mice was also confirmed by H&E and
ORO staining of the liver tissue (Supplementary Fig. S1B). Sim-
ilar to GSD Ia patients, plasma retinol levels were significantly
increased in L-G6pc−/− mice (2.33 ± 0.18 μM) as compared to
control mice (1.23 ± 0.08 μM) (Fig. 2A).
G6pc deficiency reduces hepatic retinol levels, while
retinyl palmitate is unchanged
In contrast to plasma retinol, hepatic retinol concentrations
(6.59 ± 0.66 versus 11.57 ± 0.72 μg/g liver) as well as the total
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Figure 1. Serum retinol levels are increased in GSD Ia patients. Serum retinol levels were determined in GSD Ia patients (n = 22) and age- and sex-matched controls
(n = 20) (A). No correlation was observed between age and sex (male:  or Female: O) in GSD Ia patients (grey symbols) nor in healthy controls (black symbols) (B).
Figure 2. G6pc deficiency in mice increases plasma retinol and reduces hepatic retinol, while retinyl palmitate remains unchanged. Ten days after tamoxifen-induced
deletion of the G6pc gene in hepatocytes, L-G6pc−/− and control mice (n = 6 each group) were sacrificed and analyzed for (A) plasma retinol levels, (B) liver retinol
concentrations, (C) total liver retinol pool, (D) retinol concentrations in WAT, (E) liver retinyl palmitate concentrations, (F) total liver retinyl palmitate pool and (G) retinyl
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Table I. GSD 1a patient general characteristics
Mean ± SD
Gender (F/M) 14/8
Age (GSD 1a patients) 26.1 ± 10.1
Vitamin A (serum retinol; normal 1.2–2.7 μmol/L) 3.0 ± 1.0
Hypervitaminosis A: serum retinol > 2.7 μmol/L
(no/yes)
12/10
Vitamin D (serum 25(OH)D;
sufficient > 50 nmol/L)
64.6 ± 27.4
Hypovitaminosis D: serum 25(OH)D < 30 nmol/L
(no/yes)
19/3
Hepatic steatosis (no/mild/severe/unknown) 0/12/9/1
Serum Triglycerides (normal < 1.7 mmol/L) 12.7 ± 10.0
Serum Total Cholesterol (normal < 5.2 mmol/L) 7.5 ± 2.8
Osteopenia/osteoporosis (no/yes) 15/7
Kidney disease/proteinuria (normal < 1–2 g/24 h) 0.4 ± 0.7
Proteinuria (no/yes) 19/3
AST (normal < 10–40 U/L) 55.8 ± 34.1
ALT (normal < 7–56 U/L) 42.3 ± 25.8
Total bilirubin (normal < 20.5 μmol/L) 5.9 ± 1.0
yGT (normal < 48 U/L) 53.9 ± 33.1
compared to control mice (Fig. 2B and C). WAT is a second stor-
age site of vitamin A and retinol levels were similarly reduced in
WAT of L-G6pc−/− mice as compared to control mice (0.38 ± 0.02
versus 0.54 ± 0.02 μg/g WAT, respectively) (Fig. 2D).
On the other hand, hepatic retinyl palmitate levels were
not different between L-G6pc−/− mice and control mice, not
in concentration and not in the total pool (Fig. 2E and F) and
the same was observed for retinyl palmitate concentrations
in WAT (Fig. 2G). These results indicate that hepatic vitamin
A metabolism is affected in the absence of G6pc, leading to
increased levels of circulating retinol and reduced levels in liver
and WAT, while hepatic vitamin A storage is maintained.
Normal expression of vitamin A-storing enzymes,
together with increased expression of vitamin
A-hydrolyzing enzymes in L-G6pc−/− fasted-mouse liver
Hepatic retinol and retinyl ester levels are a resultant of enzymes
that catalyze the esterification of retinol (predominantly LRAT
and to a lesser extent by DGAT1), 2) enzymes that hydrolyze
retinyl esters (ATGL/PNPLA2 and PNPLA3) and 3) enzymes that
convert retinol to retinoic acids (ADH and RALDH). Moreover,
retinol promotes its own release from the liver to the circulation
by binding to retinol binding protein 4 (RBP4) in hepatocytes.
Hepatic mRNA levels of Lrat were significantly reduced in L-
G6pc−/− mice as compared to control mice (Fig. 3A). However,
LRAT protein levels appeared not different between L-G6pc−/−
and control mice (Fig. 3B). Hepatic mRNA levels of alternative
enzyme involved in retinol esterification and lipid droplet
growth (Dgat1 and Dgat2) were elevated in L-G6pc−/− mice,
but also for DGAT1 no clear increase in protein was detected
(Fig. 3A,B). Specific antibodies against DGAT2 were not available.
Hepatic mRNA levels of both Pnpla2 and Pnpla3 were strongly
induced in L-G6pc−/− mice as compared to control mice, while
Lipe mRNA levels were not changed (Fig. 3C). In line, ATGL protein
levels sharply increased in L-G6pc−/− mice and total HSL protein
levels were unchanged compared to control mice. Still, levels
of active (phosphorylated) HSL (pHSL) were high in all L-G6pc−/−
mice, while this was variable in the control mice (Fig. 3C). Hepatic
mRNA levels of Rbp4 were similar in control and L-G6pc−/− mice
(Fig. 3D). It is important to note, however, that hepatic and serum
RBP4 protein levels are primarily regulated by the availability of
retinol in the liver, where retinol binding promotes the secretion
of RBP4 from hepatocytes (16). Conversely, the absence of retinol
leads to strong hepatic accumulation of RBP4 even at stable
Rbp4 mRNA levels, as observed in vitamin A-deficient mice
(see Supplementary Fig. S2) and also observed in rat (17). Thus
RBP4 protein levels were analyzed next. RBP4 protein levels in
livers and WAT of L-G6pc−/− mice were similar to control mice
(Fig. 4A and B, notably, hepatic RBP4 sometimes appears as a
double band in western blot analyses, as observed by others (18–
20), but with unknown cause). In contrast, serum RBP4 levels
in L-G6pc−/− mice were clearly elevated ∼3-fold compared to
control mice (Fig. 4C). Sera of GSD Ia patients also contained
significantly elevated levels of RBP4 compared to age- and sex-
matched healthy control (Fig. 4D). Serum retinol levels were
largely in line with serum RBP4 levels in healthy controls, while
such association was less evident in GSD Ia patients (Fig. 4D).
G6pc deficiency suppresses the expression
of retinoic acid-responsive Cyp26a1
Next, we aimed to analyze whether G6pc deficiency may affect
the production of retinoic acids in the liver. Hepatic mRNA
levels of Hsd17b13, a recently identified retinol dehydrogenase
(21) and all 4 retinaldehyde dehydrogenases (Raldh1–4) were
hardly affected by the absence of GSD Ia in mice (Fig. 5). Only
a small significant increase in Raldh2 and decrease in Raldh4
were observed in G6pc deficient mice. However, mRNA levels of
the highly retinoic acid-sensitive Cyp26a1 were strongly (89%)
decreased (Fig. 5) compared to control mice. Unfortunately, spe-
cific antibodies against mouse Cyp26a1 were not available to
confirm the effect of G6pc deficiency at the CYP26A1 protein
level.
Liver-specific G6pc deficiency in mice does not
cause hepatic inflammation, nor fibrosis
Finally, we analyzed whether abnormal vitamin A metabolism
in L-G6pc−/− mice leads to hepatic inflammation and/or fibrosis.
Hepatic mRNA levels of markers of inflammation, e.g. Cd68, Tnfα,
Nos2, Ccl2, Il6 were reduced in L-G6pc−/− mice as compared to
control mice (Fig. 6A). A similar suppression of hepatic mRNA
levels of markers of fibrosis, e.g. Coll1a1, Acta2, Tgf-β and Timp1,
was observed in L-G6pc−/− mice as compared to control mice
(Fig. 6B).
Taken together, our data show that G6pc deficiency leads to
elevated serum retinol and RBP4 levels in humans and in mice.
In contrast, hepatic retinol levels are reduced, most probably
because of enhanced mobilization of retinol from retinyl ester
stores and subsequent RBP4-mediated release from hepatocytes.
Discussion
This study shows for the first time that G6pc deficiency in
human and mouse is associated with elevated levels of circulat-
ing retinol, concomitantly with an increase of circulating RBP4
levels. On the contrary, retinol levels are reduced in the liver and
WAT. Tissue retinyl palmitate levels are not changed in liver-
specific G6pc deficient mice, at least not within 10 days after
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Figure 3. Hepatic expression of genes involved in vitamin A storage, hydrolysis and export in L-G6pc−/− fasted-mice. Ten days after tamoxifen-induced deletion of
the G6pc gene in hepatocytes, L-G6pc−/− and control mice (n = 6 each group) were sacrificed and analyzed by Q-PCR (A, C and D) and Western blot analysis (n = 4 each
group) (B) for hepatic expression of genes/proteins involved in (A) retinyl ester formation (Lrat, Dgat1 and Dagt2), (B) protein levels of LRAT, DGAT1, ATGL, pHSL, HSL,
β-ACTIN and Ponceau S stainings (loading control), (C) retinol synthesis (Pnpla2/Atgl and Pnpla3) and (D) retinol export from the liver (Rbp4). Transcript analyses suggest
that the balance between vitamin A storage/retinol synthesis in the liver shifts to retinol synthesis in L-G6pc−/− mice.
suggests that metabolism of retinyl ester to retinol that may
promote the secretion of retinol-bound RBP4 to the circulation.
A persistent increase in circulatory retinol may contribute to
symptoms of GSD Ia patients and aggravate steatosis and osteo-
porosis.
Clinical management of GSD Ia is primarily aimed at
maintaining steady circulating glucose levels by strictly con-
trolled intake of dietary carbohydrates during day and night.
Because of the impaired ability to produce glucose from
glucose-6-phosphate (G6P), cellular glycogen content increases,
in conjugation with elevated triglyceride storage leading to
steatosis. GSD Ia is associated with hypovitaminosis D, which
has been linked to the development of osteoporosis in these
patients (3, 22). As fatty liver disease is associated with
hypovitaminosis A (9, 10), we were interested whether GSD Ia
patients may also show aberrant circulating vitamin A levels. To
our surprise, we found that circulating retinol revels, as well
as RBP4 levels, were significantly elevated, instead of being
reduced, in GSD Ia patients and L-G6pc−/− mice. Apart from
cases of excessive dietary vitamin A intake, elevated circulating
retinol levels are a rare phenomenon. Serum retinol levels
are, however, not a sensitive measure of sharp fluctuations in
dietary intake of vitamin A as early work showed that daily
retinyl palmitate supplementation in a range of 0 to 36 000 IU
(= 0–12 times the RDA [Recommended Daily Allowance])
increased serum retinol levels by only 2% (= 0.04 μM) per 10 000 IU
vitamin A (23). On average, we observed a 28% increase in
serum retinol levels in GSD Ia patients compared to healthy
controls, with 45% of the patients showing levels above the
normal range. Thus, even though GSD Ia patients are often
prescribed multivitamin supplements, it is unlikely to cause the
increased circulating retinol levels in these patients. Notably, the
incidence of hypervitaminosis A in GSD Ia patients in our study
was higher than that of hypovitaminosis D. Impaired kidney
function, a condition associated with GSD Ia (24), may also lead
to elevated serum retinol levels (25, 26). However, in our study
GSD Ia patients did not show severe kidney disease, protein
ureia was elevated only in three GSD Ia patients. Moreover,
the liver-specific G6pc−/− mice also showed markedly elevated
retinol levels, while these animal do not develop any kidney
abnormalities, not even 15 months after ablation of the gene
in the liver (15). Thus, hepatic vitamin A metabolism likely
contributes to the elevated serum levels of retinol and RBP4
in GSD Ia. In contrast to blood, tissue retinol levels in the liver
and WAT were reduced in L-G6pc−/− mice compared to controls,
while retinyl palmitate, the main storage form of vitamin A in
the liver, was not changed. Indeed, protein levels of LRAT, the
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Figure 4. Serum RBP4 levels are elevated in L-G6pc−/− mice and GSD Ia patients. (A–C) Ten days after tamoxifen-induced deletion of the G6pc gene in hepatocytes,
L-G6pc−/− and control mice (n = 4 each group) were sacrificed and analyzed by Western blotting for RBP4 protein levels in (A) liver, (B) WAT and (C) plasma. (D) Similarly,
RBP4 protein levels were analyzed in sera of age- and sex-matched healthy controls and GSD Ia patients (n = 6 each group). β-ACTIN and Ponceau S stainings are included
as loading controls. Protein signal intensities were quantified and are shown to the right.
normal in L-G6pc−/− mice. Remarkably, though, Lrat mRNA levels
were significantly reduced in L-G6pc−/− mice. It remains to be
determined why LRAT protein levels do not follow mRNA levels.
One possibility is that LRAT is a stable protein and that it takes
>10 days after G6pc gene deletion to observe a significant effect
of LRAT protein. Expression profiling revealed an induction of
retinyl ester-hydrolyzing activity and a reduction of retinoic acid
catabolism. De novo lipogenesis is increased in G6PC deficiency
and activation of the carbohydrate-response-element-binding
protein (ChREBP) likely contributes to this phenomenon (27, 28).
Hepatic Chrebp mRNA levels were indeed increased in L-G6pc−/−
mice compared to controls (Supplementary Fig. S3). Notably,
PNPLA3 expression is controlled by ChREBP (29) and NAFLD
patients carrying the PNPLA3-I148M variant show reduced
circulating retinol levels and enhanced hepatic retinyl palmitate
contents (30, 31). Thus, ChREBP-mediated induction of PNPLA3,
together with elevated levels of ATGL and possibly pHSL may
contribute to the enhanced conversion of hepatic retinyl esters
to retinol. The strong reduction in Cyp26a1 mRNA levels in L-
G6pc−/− mice primarily hints to reduced production of retinoic
acids, as they are potent inducers of Cyp26a1 transcription
(5). Enhanced hepatic retinyl ester-hydrolysis and reduced
retinoic acid catabolism are theoretically expected to lead to
accumulation of retinol. However, hepatic retinol levels were
actually reduced, while an increase was observed circulatory
retinol and RBP4 in GDS Ia patients and L-G6pc−/− mice.
Enhanced retinol production in the liver promotes its own
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Figure 5. Gene expression of retinoic acid-responsive Cyp26a1 is strongly suppressed in the livers of L-G6pc−/− mice. Ten days after tamoxifen-induced deletion of
the G6pc gene in hepatocytes, L-G6pc−/− and control mice (n = 6 each group) were sacrificed and analyzed by Q-PCR for hepatic mRNA levels of genes involved in the
conversion of retinol to retinoic acids (Hsd1713, Raldh1, Raldh2, Raldh3, Raldh4) or catabolism of retinoic acids (Cyp26a1). Transcriptional regulation of Cyp26a1 is highly
responsive to retinoic acids.
and contributes to elevated plasma levels of retinol and RBP4
(32–34). Thus, we hypothesize that an enhanced production
of retinol pushes itself out of the liver and contributes to
the elevated serum levels of RBP4 and retinol found in GSD
Ia patients and L-G6pc−/− mice. The reduced hepatic retinol
levels may be an early response to the induced deletion of
the G6pc gene in this mouse model (10 days gene deletion).
Future studies may include L-G6pc mice after long-term gene
deletion (15) to determine whether the low hepatic retinol levels
persist.
Normal serum retinol levels range from 1.2 to 2.7 μmol/L in
the Dutch population (35), thus the average level detected in
GSD Ia patients is just above the higher end. This will not cause
acute toxicity, but chronically elevated retinol in circulation may
contribute to clinical symptoms associated with GSD Ia, espe-
cially in GSD Ia patients with levels above 4–5 μmol/L. Hyper-
vitaminosis A promotes osteoclast formation, skeleton fragility
and osteoporosis due to decreased cortical bone mass and bone
formation (36). Hypervitaminosis A-associated osteoporosis may
already occur at twice the recommended daily allowances (RDA)
of vitamin A, which will not even lead to elevated serum retinol
levels (36, 37). Osteoporosis is also observed in GSD Ia patients
and typically linked to hypovitaminosis D, which is analyzed
in routine surveillance (1, 3). Abnormal vitamin D and A levels
may synergize in aberrant bone homeostasis and may need to be
monitored both to prevent this complication in GSD Ia patients.
In fact, there are quite a few additional commonalities in symp-
toms in GSD Ia and hypervitaminosis A, like impaired growth,
dizziness and irritability (38–41). Though these symptoms likely
primarily result of poorly controlled blood glucose levels, it could
be that chronically elevated serum retinol levels may also con-
tribute to such symptoms. Hypervitaminosis A causes hepatic
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Figure 6. Hepatic G6pc-deficiency suppresses basal levels of inflammation and fibrosis in mice. Ten days after tamoxifen-induced deletion of the G6pc gene in
hepatocytes, L-G6pc−/− and control mice (n = 6 each group) were sacrificed and analyzed by Q-PCR for hepatic mRNA levels of markers of (A) inflammation (Cd68,
Tnfα, Nos2, Ccl2 and Il6) or (B) fibrosis (Col1a1, Acta2, Tgf-β and Timp1). Both markers of inflammatory and fibrosis were not increased in L-G6pc−/− livers. Instead, a
significant reduction was observed for hepatic expression of Cd68, Tnfα and Timp1 in L-G6pc−/− mice compared to controls, while all other markers showed similar
trends.
Increased circulating retinol has been found to reduce the
risk for hepatocellular carcinoma (HCC) (44, 45). GSD Ia patients
are actually at risk for the development of hepatic adenomas
that may progress to HCC. The effects on retinol and tumor
development in GSD Ia therefore appear counterintuitive. How-
ever, hepatic retinol levels are reduced and may promote ade-
noma development specifically in the liver. Here also, it is of
interest what the long-term effect is of the absence of hepatic
G6PC activity on vitamin A metabolism in the liver (15). It may
very well be that hepatic vitamin A stores get depleted in the
long-term and predispose to liver tumor development in GSD
Ia. One older patient indeed showed very low-circulating retinol
levels (Fig. 1B), which suggests extremely low hepatic vitamin A
stores.
The hepatic pathologies and disturbed vitamin A metabolism
did not induce an inflammatory or fibrotic response in livers of
L-G6pc−/− mice. In fact, all tested markers for hepatic inflam-
mation and fibrosis were suppressed to greater or lesser extent
in L-G6pc−/− mice. This may also be a result of changes in
hepatic retinol metabolism as vitamin A metabolites are potent
controllers of hepatic inflammation and fibrosis (46, 47).
Management of hypervitaminosis A is currently limited to
controlling the dietary intake of vitamin A. Given the ‘metabolic
origin’ of hypervitaminosis A in GSD Ia patients, it is important
to monitor circulating retinol levels and refrain from vitamin
A supplementation when plasma retinol levels are close to or
above normal levels. Future studies need to establish the course
of vitamin A levels in the absence of G6PC activity in patients
and/or mice in order to determine the necessity of manage-
ment of vitamin A levels in early and late stages of disease
development.
Taken together, our study shows that vitamin A metabolism
is disturbed in the absence of G6PC activity in mice and GSD
Ia patients, resulting in elevated circulating retinol levels. This
condition may contribute to various symptoms of GSD Ia, in par-
ticular, osteoporosis, which has been linked to hypovitaminosis
D in these patients so far. Vitamin A is thus a second vitamin
that needs attention in the management of GSD Ia.
Materials and Methods
Patients
The study was performed in accordance with the Declaration
of Helsinki and the institutional rules for studying biological
rest materials. Retinol analysis was performed in serum sam-
ples from 22 genetically confirmed GSD Ia patients (male n = 9
and female n = 13), who visited the Beatrix Children’ Hospi-
tal, UMCG. Samples were randomly obtained during the day.
The controls included 20 healthy, age- and sex-matched control
subjects (male n = 8 and female n = 12) aged between 10 and
45 years.
Animal model
The tamoxifen-inducible hepatocyte-specific G6pc-knock-out
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liver-specific pathologies of GSD Ia (15). Briefly, G6pc recom-
binant mice with two loxP sites flank G6pc exon 3 (B.G6pclox/w)
were crossed with transgenic mice expressing the tamoxifen-
inducible recombinase (CREERT2) under control of the serum
albumin promoter to confer hepatocyte-specific expression in
B6.SAcreERT2/w mutant mice. Male B6.G6pcex3lox/ex3lox.SACreERT2/+
mice (8–12 weeks old) were injected intraperitoneally once
daily with 100 μl tamoxifen (10 mg/ml, Sigma–Aldrich) for
five consecutive days to obtain L-G6pc−/− mice. All mice were
sacrificed 10 days after the last tamoxifen injection. Animal
experiments were performed after approval of all procedures by
the Institutional Animal Care and Use Committee, University of
Groningen, the Netherlands. All animals (n = 6–7) were kept in an
environment with alternating dark and light cycles (07:00 p.m.–
07:00 a.m.), with controlled temperature (20–24◦C) and relative
humidity (55% ± 15%) and ad libitum access to food and water.
Prior to sacrifice, the mice were fasted from 10:00 p.m. until
08:00 a.m. the next day. Tissue and plasma samples were
collected for further analysis.
Standard protocols for histochemistry and quantification of
serum/tissue cholesterol, triglyceride, retinol, retinyl esters,
mRNA (quantitative reverse transcription-polymerase chain
reaction [qRT-PCR]), protein (Western blotting) and the corre-
sponding statistical analyses are presented in Supplementary
Material and Methods.
Supplementary Material
Supplementary Material is available at HMG online.
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